170 related articles for article (PubMed ID: 23371259)
41. Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.
Smolej L
Curr Cancer Drug Targets; 2016; 16(8):710-720. PubMed ID: 27055578
[TBL] [Abstract][Full Text] [Related]
42. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
[TBL] [Abstract][Full Text] [Related]
43. How I treat elderly or comorbid patients with chronic lymphocytic leukemia.
Smolej L
Acta Medica (Hradec Kralove); 2010; 53(4):213-20. PubMed ID: 21400979
[TBL] [Abstract][Full Text] [Related]
44. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
45. Modern concepts in the treatment of chronic lymphocytic leukemia.
Smolej L
Hematology; 2009 Oct; 14(5):249-54. PubMed ID: 19843378
[TBL] [Abstract][Full Text] [Related]
46. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
47. [Chronic lymphocytic leukemia: current standards and novel approaches].
Tausch E; Stilgenbauer S
Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
[TBL] [Abstract][Full Text] [Related]
48. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
[TBL] [Abstract][Full Text] [Related]
49. [Breast cancer. Individualized therapy concepts].
Harbeck N; Wuerstlein R
Internist (Berl); 2013 Feb; 54(2):194-9. PubMed ID: 23371261
[TBL] [Abstract][Full Text] [Related]
50. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia.
Winkler D; Döhner H; Stilgenbauer S
Curr Drug Targets; 2006 Oct; 7(10):1313-27. PubMed ID: 17073593
[TBL] [Abstract][Full Text] [Related]
51. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
52. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
53. Chronic lymphocytic leukemia (CLL)-Then and now.
Rai KR; Jain P
Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
[TBL] [Abstract][Full Text] [Related]
54. Management of chronic lymphocytic leukemia.
Stilgenbauer S; Furman RR; Zent CS
Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
[TBL] [Abstract][Full Text] [Related]
55. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
56. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
57. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.
Moreno C; Villamor N; Colomer D; Esteve J; Martino R; Nomdedéu J; Bosch F; López-Guillermo A; Campo E; Sierra J; Montserrat E
J Clin Oncol; 2005 May; 23(15):3433-8. PubMed ID: 15809449
[TBL] [Abstract][Full Text] [Related]
59. [Personalized therapy concepts for malignant melanoma].
Schlaak M; Kreuzberg N; Mauch C; Kurschat P
Internist (Berl); 2013 Feb; 54(2):188-93. PubMed ID: 23371260
[TBL] [Abstract][Full Text] [Related]
60. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Rossi D; Terzi-di-Bergamo L; De Paoli L; Cerri M; Ghilardi G; Chiarenza A; Bulian P; Visco C; Mauro FR; Morabito F; Cortelezzi A; Zaja F; Forconi F; Laurenti L; Del Giudice I; Gentile M; Vincelli I; Motta M; Coscia M; Rigolin GM; Tedeschi A; Neri A; Marasca R; Perbellini O; Moreno C; Del Poeta G; Massaia M; Zinzani PL; Montillo M; Cuneo A; Gattei V; Foà R; Gaidano G
Blood; 2015 Oct; 126(16):1921-4. PubMed ID: 26276669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
